Physicians' Academy for Cardiovascular Education

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome

Video navigation menu

  • Residual inflammatory risk versus residual cholesterol risk 00:23
  • Lowering hsCRP to reduce CV events 02:21
  • Targeting inflammatory pathways for the treatment of CVD 04:27
  • From CRP to IL-6 to IL-1: moving upstream to identify novel targets for atheroprotection 05:37
  • CIRT trial: low-dose methotrexate for reducing CV events 06:45
  • CANTOS-trial (canakinumab): background and design 08:18
  • Other ongoing areas of inflammation biology 11:14

Educational information

The educational objectives of this symposum were to:

Faculty

Paul M Ridker, MD, MPH: Eugene Braunwald Professor of Medicine, Harvard Medical School, Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, Massachusetts

Disclosures

This EBAC accredited symposium was funded by an unrestricted educational grants received from Novartis, MSD, Amgen

Also watch lecture: Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies by prof Erik Stroes, MD – AMC, Amsterdam, The Netherlands Also watch lecture: Beyond statins: The role of ezetimibe in targeting residual risk - by prof Chris Packard, MD, University of Glasgow, United Kingdom